These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 6895407)

  • 1. [Clearance concept applied to pharmacokinetics: 1. Application for the study of tolamolol (beta-blocking agent) in healthy volunteers (author's transl)].
    Balant L; Faulkner JK; Tozer TN
    Nephrologie; 1980; 1(4):172-6. PubMed ID: 6895407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)].
    Balant L; Gorgia A; Marmy A; Tschopp JM
    Nephrologie; 1980; 1(4):177-82. PubMed ID: 6895408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consequences of renal insufficiency on the hepatic clearance of some drugs.
    Balant LP; Dayer P; Fabre J
    Int J Clin Pharmacol Res; 1983; 3(6):459-74. PubMed ID: 6147317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of metabolites in the relationship between pharmacokinetics and the effect of beta blockers. Studies on tolamolol and bufuralol].
    Tschopp JM; Gorgia A; Balant L; Revillard C; Francis RJ; Fabre FJ
    Schweiz Med Wochenschr; 1978 May; 108(20):756-64. PubMed ID: 26114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of the beta-receptor blocker metipranolol in patients with liver cirrhosis (author's transl)].
    Seyfried C; Ledermann H; Rennekamp H; L'age M; Abshagen U
    Dtsch Med Wochenschr; 1982 Jan; 107(1):21-6. PubMed ID: 6120063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatic clearance of drugs. Physiological and pharmacokinetic considerations].
    Pellegrin P; Lesne M
    J Pharmacol; 1983; 14(2):107-39. PubMed ID: 6865443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on absorption, distribution, metabolism and excretion of bunitrolol, a beta-adrenergic blocking agent, in rats and mice.
    Suzuki T; Rikihisa T
    Arzneimittelforschung; 1979; 29(11):1707-15. PubMed ID: 44473
    [No Abstract]   [Full Text] [Related]  

  • 9. [Multiple-dose pharmacokinetics of paracetamol and salicylamide in man after combined rectal application (author's transl)].
    Liedtke R; Ebel S; Missler B; Haase W; Stein L
    Arzneimittelforschung; 1980; 30(8):1295-8. PubMed ID: 7192145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools.
    De Buck SS; Sinha VK; Fenu LA; Gilissen RA; Mackie CE; Nijsen MJ
    Drug Metab Dispos; 2007 Apr; 35(4):649-59. PubMed ID: 17267621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans.
    Kiriyama A; Honbo A; Iga K
    Int J Pharm; 2008 Feb; 349(1-2):53-60. PubMed ID: 17765415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics.
    Iwatsubo T; Hirota N; Ooie T; Suzuki H; Sugiyama Y
    Biopharm Drug Dispos; 1996 May; 17(4):273-310. PubMed ID: 8845471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism.
    Cong D; Doherty M; Pang KS
    Drug Metab Dispos; 2000 Feb; 28(2):224-35. PubMed ID: 10640522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic perturbations in kidney failure. Anomalies of metabolites and tissue diffusion (author's transl)].
    Fabre J; Balant L; Rudhardt M; Blanchard P
    Nouv Presse Med; 1979 Aug 25-Sep 3; 8(33):2677-82. PubMed ID: 114976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of midazolam after i.v. administration (author's transl)].
    Amrein R; Cano JP; Eckert M; Coassolo P
    Arzneimittelforschung; 1981; 31(12a):2202-5. PubMed ID: 7199322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro-in vivo extrapolation of quantitative hepatic biotransformation data for fish. I. A review of methods, and strategies for incorporating intrinsic clearance estimates into chemical kinetic models.
    Nichols JW; Schultz IR; Fitzsimmons PN
    Aquat Toxicol; 2006 Jun; 78(1):74-90. PubMed ID: 16513189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and metabolism of zopiclone.
    Gaillot J; Heusse D; Hougton GW; Marc Aurele J; Dreyfus JF
    Int Pharmacopsychiatry; 1982; 17 Suppl 2():76-91. PubMed ID: 7188377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of human pharmacokinetics--gut-wall metabolism.
    Fagerholm U
    J Pharm Pharmacol; 2007 Oct; 59(10):1335-43. PubMed ID: 17910807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.